Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%

Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lVIyPuW
via IFTTT

Read More

Omron Healthcare eyes Chennai as global manufacturing hub, targets 3 million BP monitors by 2028

Omron Healthcare has commenced full-scale production at its new facility near Chennai for blood pressure monitors. The company aims to produce three million monitors annually by 2028 for the Indian market. Initially, all produced devices will serve local consumers to address cardiovascular health challenges. Omron is also working towards increasing domestic sourcing of components to support local manufacturing initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2JSVslj
via IFTTT

Read More

NPPA list brings little relief: No price cut for 25% cancer drugs

Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across 643 packs is 38.22%. Several high-cost patented medicines remain unchanged, prompting patient advocates to question how much relief the trade-margin cap will actually deliver when the new prices take effect on November 9.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hqpvYDO
via IFTTT

Read More

India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil

India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driven by strong demand from Europe, ASEAN, and Latin America. Shipments included drug formulations, biologicals, bulk drugs, and surgical products. Exports to key regions, particularly Europe and ASEAN, rose significantly during this period. Industry leaders emphasized the need for India to enhance its pharmaceutical innovation and manufacturing capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1prYPNv
via IFTTT

Read More

Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal

In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhrKOSZ
via IFTTT

Read More

SC pulls up Centre over soaring medicine costs

The Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sandeep Mehta questioned the justification for significant price discrepancies faced by patients. The court highlighted a lack of accountability regarding how drug manufacturers benefit from inflated prices. Government representatives stated that regulatory measures should not encompass the entire drug pricing ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKD2ST4
via IFTTT

Read More

Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q27gIB0
via IFTTT

Read More